PMID- 27760950
OWN - NLM
STAT- MEDLINE
DCOM- 20170127
LR  - 20170127
IS  - 0385-0684 (Print)
IS  - 0385-0684 (Linking)
VI  - 43
IP  - 10
DP  - 2016 Oct
TI  - [Development of Peptide Vaccines for Triple-Negative Breast Cancer Treatment].
PG  - 1249-1251
AB  - Our previous phase II clinical trial showed that therapeutically selected 
      personalized peptide vaccines(PPVs)were effective at boosting anticancer 
      immunity; the immune response after PPV was associated with a clinical outcome as 
      a prognostic factor for metastatic breast cancer(mBC). We conducted an early 
      phase II study to evaluate the safety and efficacy of a new regimen using 
      multiple peptide vaccines(KRM-19)for patients with metastatictriple -negative 
      breast cancer. KRM-19 consisted of 19 mixed peptides chosen from the previously 
      reported 31 PPVs according to their anti-tumor immunologiceffec ts and safety 
      profiles for patients with mBC. All patients had histologically confirmed 
      measurable ER-PgR-HER2- mBC and their human leukocyte antigen(HLA) / -A molecules 
      were A2, A3, A11, A24, A26, A31, or A33. KRM-19(19mg/mL)was administrated 
      subcutaneously every week for a total of 6 doses. Concurrent conventional chemo- 
      and/or endocrine therapy were not permitted during treatment. This was an 
      open-label, early phase II study. The primary endpoint was safety and anti-tumor 
      immunologic effect, while the secondary endpoints were clinical responses and 
      progression-free survival(PFS). The estimated enrollment was 10-15 and 8 patients 
      were enrolled(Clinical trial registry number: UMIN000014616). Measurement of 
      peptide-specific cytotoxic T lymphocyte and IgG responses were conducted before 
      and after vaccination. The correlation between PFS and the increased IgG response 
      and/or CTL levels were investigated.
FAU - Toh, Uhi
AU  - Toh U
AD  - Dept. of Surgery Kurume University School of Medicine.
FAU - Saku, Shuko
AU  - Saku S
FAU - Okabe, Mina
AU  - Okabe M
FAU - Iwakuma, Nobutaka
AU  - Iwakuma N
FAU - Kimitsuki, Yuko
AU  - Kimitsuki Y
FAU - Akashi, Momoko
AU  - Akashi M
FAU - Ogo, Etsuyo
AU  - Ogo E
FAU - Yamada, Akira
AU  - Yamada A
FAU - Shichijo, Shigeki
AU  - Shichijo S
FAU - Itoh, Kyogo
AU  - Itoh K
FAU - Akagi, Yoshito
AU  - Akagi Y
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Gan To Kagaku Ryoho
JT  - Gan to kagaku ryoho. Cancer & chemotherapy
JID - 7810034
RN  - 0 (Cancer Vaccines)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Cancer Vaccines/adverse effects/immunology/*therapeutic use
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Triple Negative Breast Neoplasms/*drug therapy/immunology
MH  - Vaccines, Subunit/adverse effects/immunology/therapeutic use
EDAT- 2016/10/21 06:00
MHDA- 2017/01/28 06:00
CRDT- 2016/10/21 06:00
PHST- 2016/10/21 06:00 [pubmed]
PHST- 2017/01/28 06:00 [medline]
PHST- 2016/10/21 06:00 [entrez]
PST - ppublish
SO  - Gan To Kagaku Ryoho. 2016 Oct;43(10):1249-1251.